Search This Blog

Monday, December 23, 2019

NewLink +16% on NLG207 license agreement

NewLink Genetics (NASDAQ:NLNKenters into a license agreement with Ellipses Pharma.
Ellipses bought NLNK’s inventory of NLG207 related materials and gained the rights to develop and commercialize CRLX-301.
NewLink has the potential to receive future royalties or economic share related to NLG207.
NLNK shares are up 16.4% after hours to $2.27.

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.